Upcoming Webinars
“Using PBPK modeling to assess the impact of diseases on oral drug absorption: a tale of 2 drugs”
Wednesday, June 29, 2022
5 AM CEST (Paris) / 8 AM PT (Los Angeles) / 11 AM ET (New York)
Randomized clinical trial is the most effective way to determine whether a cause-and-effect relationship exists between an intervention and a predefined clinical outcome. Much attention has been paid to the internal validity of a clinical trial, i.e. the extent to which the design and conduct of a trial eliminates the possibility of bias. In this webinar, we will go over two case studies leveraging IVIVE-PBPK modeling to prospect the impact of HIV and cystic fibrosis on the oral absorption of two broadly prescribed BCS 2 drugs.
Presenter:
Dr. Rodrigo Cristofoletti
Assistant Professor, Center for Pharmacometrics & Systems Pharmacology, Dept. of Pharmaceutics
University of Florida
“Predicting pharmacokinetics of multisource acyclovir oral products through Physiologically Based Biopharmaceutics Modeling”
Wednesday, July 13, 2022
5 AM CEST (Paris) / 8 AM PT (Los Angeles) / 11 AM ET (New York)
Highly variable disposition after oral ingestion of acyclovir has been reported, although little is known regarding the underlying mechanisms. Different studies using the same reference product (Zovirax ®) showed that Cmax and AUC were respectively 44 and 35% lower in Saudi Arabians than Europeans, consistent with higher frequencies of reduced-activity polymorphs of the organic cation transporter (OCT1) in Europeans. This webinar will explore this study in depth.
Presenters:
Dr. Peter Langguth, University Professor at Johannes Gutenberg University Mainz
Dr. Mauricio A. Garcia, PhD student/Research Assistant, Johannes Gutenberg University Mainz
Watch Past Webinars
DILIsym® Applications in Drug Development – Perspectives from 2 Pharma Industry Executives & an Experienced Consultant
What do NURTEC™ ODT, TURALIO®, lixivaptan, solithromycin, JYNARQUE®, VEKLURI®, and UBRELVY® have in common?
Stream
Modeling and Simulation of a parent-metabolite-PD datatset (Spring School challenge solution)
Whether you have participated to our Spring School and its modeling challenge or not, this webinar is for you!
Stream
Human-on-a-Chip combined with PBPK modeling for in vitro/in vivo PK/PD extrapolation
Human-on-a-Chip (HoaC) systems are becoming valuable tools to study, understand disease physiology, and expand the prediction of pharmacodynamic effects before first-in-human studies. They can also be used to evaluate the toxic effects of compounds in non-pharma industries where these effects cannot be examined in vivo.
Stream Download
New Library of Tumor Growth Inhibition Models in Monolix
Presentation of the models in the TGI library available in Monolix and Simulx
Stream
Strategic Implementation of Model-informed Drug Development (MIDD) for Regulatory Success
In honor of the International Day of Women and Girls in Science, she will also share and reflect on some of her early career experiences.
Stream
